Pune, India -- (SBWIRE) -- 05/23/2018 -- Global Anti-Nuclear Antibody Test Market is expected to reach USD 1,964.47 million by 2025 from USD 1,093.40 million in 2017, at a CAGR of 7.7% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Here is the Solution! Click Here For Free Sample Report @: http://databridgemarketresearch.com/request-a-sample/?dbmr=global-antinuclear-antibody-test-market

Segmentation: Global Anti-Nuclear Antibody Test Market

Global Anti-Nuclear Antibody Test Market Product (Assay Kits & Reagents, Systems, Software), Test (Indirect Immunofluorescence, ELISA, Multiplex Testing), Disease (Systemic Lupus Erythematosus, Sjögren's Syndrome, Rheumatoid Arthritis, Scleroderma, Polymyositis), End-User (Hospitals, Clinics, Physician Office Laboratories), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)-Industry Trends and Forecast to 2025

Some of the Major Players Operating in this Market are:-

- Bio-Rad Laboratories Inc.,
- Alere,
- Trinity Biotech,
- Thermo Fisher Scientific Inc.,
- Antibodies Inc.,
- EUROIMMUN AG, and
- Immuno Concepts among others.

First time buyer? check offers and avail 10% Discount on Direct Purchase "Global Anti-Nuclear Antibody Test Market " Or kindly send the email at sopan.gedam@databridgemarketresearch.com

Drivers: Global Anti-Nuclear Antibody Test Market

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

INCREASING INCIDENCE OF AUTOIMMUNE DISEASES

The autoimmune diseases are the diseases in which immune system attacks healthy cells. Autoimmune diseases includes rheumatoid arthritis, lupus, celiac disease, Sjögren's syndrome, polymyalgia rheumatic, multiple sclerosis, ankylosing spondylitis, alopecia areata, temporal arteritis and others. The antinuclear antibodies tests are used to diagnose these autoimmune diseases as these are high-morbidity and moderate-mortality chronic conditions.

The increasing number of autoimmune diseases requires more number of ANA tests to be performed for the diagnosis. With the rising number of diagnostic tests, demand of ANA test kits and other products are also increasing which is ultimately boosting the market to grow.

RISING MEDICAL INSURANCE

The fittest folks may only need a primary care physician, but a person with autoimmune disorders may need an entire team of specialists along with health insurance payer. The causes of autoimmune disorders such as lupus, diabetes (type 1), rheumatoid arthritis, and Sjogren's syndrome have not been determined, but an abnormal immune response is the common feature. Due to the chronic nature of these disorders, the financial cost to both patients and insurers is often high.

Medical or life insurance with an autoimmune disease can either be relatively easy or difficult completely depends on the severity of the condition and significant medical disclosures. The some insurance providers will provide immediate decisions of policy for the conditions such as Multiple Sclerosis. Some autoimmune diseases are accepted at normal terms by insurance providers whereas serious conditions are accepted at higher prices or declined altogether.

Any Specific Requirements? Questions? Ask to Our Industry Expert @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-antinuclear-antibody-test-market

As per the Congressional Budget Office (CBO) and Joint Committee on Taxation (JCT), the enactment of the Patients Protection and Affordable Care Act (PPACA) will increase the share of patient aged below 65 years with insurance from 80.0% in 2012 to 89.0% by 2022, in U.S.

Health insurance coverage for autoimmune diseases in Europe has also increased. According to the Association of British Insurers, in 2015, approximately 5.1 million people were covered under private insurance in the U.K..Various initiatives taken by government to promote the diagnosis of autoimmune diseases are helping to grow the ANA testing products market

For instance, Lupus Life Insurance is often available depending upon the type of lupus, discoid lupus erythematosus (DLE) or systemic lupus erythematosus (SLE). Rates for DLE are usually better than those for SLE however depending upon the severity and frequency of symptoms. Insurers offer more favorable terms to non-smokers than smokers who are combined with lupus. According to Lupus Foundation of America, the average healthcare cost annually for a patient with lupus is approximately USD 12,643.0.

Considering the chronic nature of various autoimmune diseases, they have a significant importance on medical care utilization involving significant direct and indirect treatment costs, and affect the quality of life of patients. Thus, the high prevalence of autoimmune disorder is an indicator of the steady growth of the global anti-nuclear antibody test market.

RISE IN GOVERNMENT HEALTHCARE PROTECTION

In February 2014, National Institutes of Health (NIH), biopharmaceutical companies, and multiple non-profit organizations launched first-time new public-private partnership to identify and validate the most capable biological targets for therapeutics. Foundation for the NIH (FNIH) managed the Accelerating Medicines Partnership (AMP) that brought high-level government, industry and non-profit foundation partners together to design the research plan for the autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus (lupus).

Therefore the rising government funding, public-private partnership and awareness programs are helping patients to take the medical treatment in a better way and they opt for the diagnosis of various autoimmune diseases. Thus government initiatives are eventually driving the ANA test market to grow.

Purchase this report online with 248 Pages, Top Key Players Analysis and List of Tables & Figure @ http://databridgemarketresearch.com/reports/global-antinuclear-antibody-test-market/

TABLE OF CONTENTS GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET

1. INTRODUCTION

1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED

2. MARKET SEGMENTATION

2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURCES
2.8. ASSUMPTIONS

3. MARKET OVERVIEW

3.1. DRIVERS

3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
3.1.2. RISING MEDICAL INSURANCE
3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION

3.2. RESTRAINTS

3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL

3.3. OPPORTUNITIES

3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
3.3.2. EMERGING MARKETS
3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET

3.4. CHALLENGES

3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

6.1. OVERVIEW
6.2. ASSAY KITS & REAGENTS
6.3. SYSTEMS
6.4. SOFTWARE

7. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

7.1. OVERVIEW
7.2. INDIRECT IMMUNOFLUORESCENCE
7.3. ELISA
7.4. MULTIPLEX TESTING

8. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

8.1. OVERVIEW
8.2. RHEUMATOID ARTHRITIS
8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
8.4. SJÖGREN'S SYNDROME
8.5. SCLERODERMA
8.6. POLYMYOSITIS
8.7. OTHERS

9. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

9.1. OVERVIEW
9.2. HOSPITALS
9.3. CLINICS
9.4. PHYSICIAN OFFICE LABORATORIES
9.5. OTHERS

10. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

10.1. OVERVIEW

10.2. NORTH AMERICA

10.2.1. U.S.
10.2.2. CANADA
10.2.3. MEXICO

10.3. EUROPE

10.3.1. GERMANY
10.3.2. FRANCE
10.3.3. U.K.
10.3.4. ITALY
10.3.5. SPAIN
10.3.6. SWITZERLAND
10.3.7. NETHERLANDS
10.3.8. BELGIUM
10.3.9. RUSSIA
10.3.10. TURKEY
10.3.11. REST OF EUROPE

10.4. ASIA-PACIFIC

10.4.1. CHINA
10.4.2. JAPAN
10.4.3. INDIA
10.4.4. SOUTH KOREA
10.4.5. AUSTRALIA
10.4.6. SINGAPORE
10.4.7. THAILAND
10.4.8. MALAYSIA
10.4.9. INDONESIA
10.4.10. PHILIPPINES
10.4.11. REST OF ASIA-PACIFIC

10.5. SOUTH AMERICA

10.5.1. BRAZIL
10.5.2. REST OF SOUTH AMERICA

10.6. MIDDLE EAST & AFRICA

10.6.1. SOUTH AFRICA
10.6.2. REST OF MIDDLE EAST & AFRICA

11. GLOBAL ANTI-NUCLEAR ANTIBODY TEST MARKET, COMPANY LANDSCAPE 220

11.1. COMPANY SHARE ANALYSIS: GLOBAL
11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
11.3. COMPANY SHARE ANALYSIS: EUROPE
11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

12.1. THERMO FISHER SCIENTIFIC INC.

12.1.1. COMPANY OVERVIEW
12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
12.1.3. PRODUCT PORTFOLIO
12.1.4. RECENT DEVELOPMENTS

12.2. MERCK KGAA

12.2.1. COMPANY OVERVIEW
12.2.2. MERCK KGAA: REVENUE ANALYSIS
12.2.3. PRODUCT PORTFOLIO
12.2.4. RECENT DEVELOPMENTS

12.3. ALERE INC.

12.3.1. COMPANY OVERVIEW
12.3.2. ALERE INC.: REVENUE ANALYSIS
12.3.3. PRODUCT PORTFOLIO
12.3.4. RECENT DEVELOPMENTS

12.4. TRINITY BIOTECH

12.4.1. COMPANY OVERVIEW
12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
12.4.3. PRODUCT PORTFOLIO
12.4.4. RECENT DEVELOPMENTS

12.5. ANTIBODIES INC.

12.5.1. COMPANY OVERVIEW

12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
12.5.3. PRODUCT PORTFOLIO
12.5.4. RECENT DEVELOPMENTS

12.6. BIO-RAD LABORATORIES, INC.

12.6.1. COMPANY OVERVIEW
12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
12.6.3. PRODUCT PORTFOLIO
12.6.4. RECENT DEVELOPMENTS

12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)

12.7.1. COMPANY OVERVIEW
12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
12.7.3. PRODUCT PORTFOLIO
12.7.4. RECENT DEVELOPMENTS

12.8. IMMUNO CONCEPTS

12.8.1. COMPANY OVERVIEW
12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
12.8.3. PRODUCT PORTFOLIO
12.8.4. RECENT DEVELOPMENTS

12.9. INOVA DIAGNOSTICS

12.9.1. COMPANY OVERVIEW
12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
12.9.3. PRODUCT PORTFOLIO
12.9.4. RECENT DEVELOPMENTS

12.10. ZEUS SCIENTIFIC, INC.

12.10.1. COMPANY OVERVIEW
12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
12.10.3. PRODUCT PORTFOLIO
12.10.4. RECENT DEVELOPMENTS

12.11. MBL INTERNATIONAL

12.11.1. COMPANY OVERVIEW
12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
12.11.3. PRODUCT PORTFOLIO
12.11.4. RECENT DEVELOPMENTS

12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD

12.12.1. COMPANY OVERVIEW
12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
12.12.3. PRODUCT PORTFOLIO
12.12.4. RECENT DEVELOPMENTS

12.13. AESKU GROUP GMBH & CO. KG

12.13.1. COMPANY OVERVIEW
12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
12.13.3. PRODUCT PORTFOLIO
12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

Questions? We'll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-antinuclear-antibody-test-market

Related Report

Global Molecular Spectroscopy Market – Industry Trends and Forecast to 2024

Global Molecular Spectroscopy Market, By Type (Nuclear Magnetic Resonance (Continuous Wave, Fourier Transform, Solid State), UV-Vis, Infrared (IR), Near Infrared (NIR), Colour Spectroscopy, Raman Spectroscopy, Others), By Applications (Pharmaceuticals, Biotech, Food and Beverages, Environmental Testing, Academics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Rest of the World) – Industry Trends and Forecast to 2024

http://databridgemarketresearch.com/reports/global-molecular-spectroscopy-market/

About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com